BMS Reports Pooled Five Year Results of Opdivo (nivolumab) in Two P-III Studies for Advanced Non-Small Cell Lung Cancer

 BMS Reports Pooled Five Year Results of Opdivo (nivolumab) in Two P-III Studies for Advanced Non-Small Cell Lung Cancer

BMS Reports Pooled Five Year Results of Opdivo (nivolumab) in Two P-III Studies for Advanced Non-Small Cell Lung Cancer

Shots:

  • The pooled analysis of the two P-III CheckMate -017 and -057 studies involves assessing of Opdivo (3 mg/kg, q2w) vs Docetaxel (75 mg/m2, q3w) in 854 patients in a ratio (1:1) with previously treated NSCLC across both squamous and non-squamous histologies
  • The P-III studies result: @5yrs. OS (13.4% vs 2.6%); patients continued to see response (32.2% vs 0%); m-DoR (19.9 vs 5.6 mos.); no new safety signals with extended follow-up
  • Opdivo is a PD-1 immune checkpoint inhibitor, harnessing the body’s own immune system to restore anti-tumor immune response and is the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world

Click here to­ read full press release/ article | Ref: BMS | Image: Law

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post